AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with the clinical development ... Read More